Findings

What do systematic reviews say?

4 questions · 4 findings · 3 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 1 · 25%GRADE not reported 0 · 0%Very low 1 · 25%Low 1 · 25%Moderate 1 · 25%High 0 · 0%

Vitamin K antagonists vs low molecular weight heparin

Minor bleeding · ambulatory patients with multiple myeloma receiving immunomodulatory agents

It is very uncertain whether vitamin K antagonist (VKA) changes minor bleeding compared with low molecular weight heparin (LMWH) (very low certainty).

1 finding from 1 review

Antithrombotic therapy for ambulatory patients with multiple myeloma receiving immunomodulatory agents 2021 · Cochrane Headline outcomes only
RR 0.33 [0.03, 3.17]
1 study · 439 participants
Very low

Vitamin K antagonist (VKA) prophylaxis vs no prophylaxis

Minor bleeding · ambulatory people with cancer without venous thromboembolism receiving systemic therapy

Vitamin K antagonist (VKA) prophylaxis probably leads to higher minor bleeding compared with no prophylaxis (moderate certainty).

1 finding from 1 review

Oral anticoagulation in people with cancer who have no therapeutic or prophylactic indication for anticoagulation 2021 · Cochrane Headline outcomes only
RR 3.14 [1.85, 5.32]
4 studies · 863 participants
Moderate

Vitamin K antagonists vs low molecular weight heparin

Minor bleeding ‐ not reported · ambulatory patients with multiple myeloma receiving immunomodulatory agents

The review found no eligible studies for this question.

1 finding from 1 review

Antithrombotic therapy for ambulatory patients with multiple myeloma receiving immunomodulatory agents 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Vitamin K antagonists vs no VKA

Minor bleeding · people with cancer with thrombosis prophylaxis and central venous catheters

Vitamin K antagonist (VKA) showed no clear difference in minor bleeding (up to 3 months) compared with no VKA (low certainty).

1 finding from 1 review

Anticoagulation for people with cancer and central venous catheters 2018 · Cochrane Headline outcomes only
RR 0.69 [0.38, 1.26]
2 studies · 1026 participants
Low